Another small step for Chinese R&D as Sihuan molecule heads towards trials
This article was originally published in Scrip
Executive Summary
The product itself may not be an innovative breakthrough, but the recent acceptance by China's State FDA of an application by Sihuan Pharmaceutical Holdings to begin domestic clinical trials with a calcium antagonist marks the continued emergence of the country's R&D capabilities.